Profile data is unavailable for this security.
About the company
Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company. The Company is focused on developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue and skeleton. The Company is also focused on developing a novel therapy to treat the rare genetic diseases of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) and ATP-Binding Cassette in the C6 family (ABCC6) Deficiencies. The Company’s lead product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to cleave extracellular adenosine triphosphate (ATP) to generate plasma pyrophosphate (PPi) and adenosine monophosphate (AMP), which can be processed to phosphate and adenosine. Its INZ-701 is in clinical development for the treatment of ENPP1 Deficiency, ABCC6 Deficiency and calciphylaxis.
- Revenue in USD (TTM)0.00
- Net income in USD-71.17m
- Incorporated2015
- Employees59.00
- LocationInozyme Pharma Inc321 SUMMER STREET, SUITE 400BOSTON 02210United StatesUSA
- Phone+1 (857) 330-4340
- Fax+1 (302) 655-5049
- Websitehttps://www.inozyme.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vanda Pharmaceuticals Inc. | 192.64m | 2.51m | 257.77m | 203.00 | 102.17 | 0.473 | 46.71 | 1.34 | 0.0439 | 0.0439 | 3.35 | 9.47 | 0.3004 | 11.60 | 5.69 | 948,965.50 | 0.3912 | 6.61 | 0.4547 | 7.62 | 92.32 | 90.55 | 1.30 | 15.18 | 4.92 | -- | 0.00 | 0.00 | -24.27 | -0.0496 | -60.02 | -36.96 | -56.77 | -- |
| Sutro Biopharma Inc | 153.73m | -106.79m | 258.17m | 302.00 | -- | 1.39 | -- | 1.68 | -1.79 | -1.79 | 2.56 | 2.45 | 0.3503 | -- | 7.12 | 509,043.00 | -24.34 | -25.48 | -29.77 | -29.75 | -- | -- | -69.47 | -113.71 | -- | -- | 0.0264 | -- | 126.84 | 31.96 | 10.41 | -- | 22.61 | -- |
| Acrivon Therapeutics Inc | 0.00 | -60.39m | 261.49m | 58.00 | -- | 1.57 | -- | -- | -2.73 | -2.73 | 0.00 | 5.38 | 0.00 | -- | -- | 0.00 | -37.80 | -- | -40.30 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -93.76 | -- | -- | -- |
| Enanta Pharmaceuticals Inc | 73.62m | -138.24m | 264.03m | 145.00 | -- | 1.38 | -- | 3.59 | -6.56 | -6.56 | 3.50 | 9.07 | 0.1897 | -- | 4.79 | 507,737.90 | -35.63 | -14.56 | -40.03 | -15.62 | -- | -- | -187.77 | -54.96 | -- | -- | 0.0074 | -- | -8.07 | -17.45 | -9.91 | -- | 24.89 | -- |
| TriSalus Life Sciences Inc | 18.51m | -63.28m | 265.71m | 112.00 | -- | -- | -- | 14.35 | -1.84 | -1.84 | 0.5991 | -0.982 | 0.7758 | 1.30 | 7.24 | 165,267.90 | -247.43 | -- | -17,440.77 | -- | 85.93 | -- | -318.95 | -- | 1.25 | -13.69 | -- | -- | 49.31 | -- | -26.51 | -- | -- | -- |
| Inozyme Pharma Inc | 0.00 | -71.17m | 267.47m | 59.00 | -- | 1.90 | -- | -- | -1.39 | -1.39 | 0.00 | 2.27 | 0.00 | -- | -- | 0.00 | -41.86 | -45.00 | -45.82 | -48.90 | -- | -- | -- | -- | -- | -- | 0.2417 | -- | -- | -- | -6.13 | -- | 2.85 | -- |
| Boundless Bio Inc | 0.00 | -49.43m | 268.43m | 72.00 | -- | -- | -- | -- | -2.22 | -2.22 | 0.00 | 5.42 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.70 | -- | -- | -- |
| Black Diamond Therapeutics Inc | 0.00 | -82.44m | 268.43m | 54.00 | -- | 2.26 | -- | -- | -1.92 | -1.92 | 0.00 | 2.26 | 0.00 | -- | -- | 0.00 | -52.37 | -40.29 | -58.91 | -43.29 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 9.57 | -- | -15.37 | -- |
| Werewolf Therapeutics Inc | 19.94m | -37.37m | 269.19m | 47.00 | -- | 2.18 | -- | 13.50 | -1.05 | -1.05 | 0.5595 | 2.85 | 0.119 | -- | 4.82 | 424,319.20 | -22.30 | -- | -25.62 | -- | -- | -- | -187.37 | -- | -- | -- | 0.2609 | -- | 21.60 | -- | 30.56 | -- | -- | -- |
| ESSA Pharma Inc | 0.00 | -25.80m | 270.74m | 50.00 | -- | 1.92 | -- | -- | -0.5851 | -0.5851 | 0.00 | 3.19 | 0.00 | -- | -- | 0.00 | -16.68 | -23.01 | -17.03 | -23.67 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 24.27 | -- | -- | -- |
| Adaptimmune Therapeutics PLC - ADR | 60.28m | -113.87m | 270.90m | 449.00 | -- | 6.09 | -- | 4.49 | -0.5218 | -0.5218 | 0.2995 | 0.1739 | 0.1972 | -- | 14.60 | 134,256.10 | -37.24 | -41.19 | -48.02 | -48.21 | -- | -- | -188.90 | -714.26 | -- | -- | 0.00 | -- | 122.05 | 0.2595 | 31.18 | -- | 0.7202 | -- |
| Rapt Therapeutics Inc | 0.00 | -116.80m | 271.44m | 131.00 | -- | 1.82 | -- | -- | -3.05 | -3.05 | 0.00 | 4.27 | 0.00 | -- | -- | 0.00 | -53.15 | -46.30 | -57.90 | -49.97 | -- | -- | -- | -3,522.72 | -- | -- | 0.00 | -- | -100.00 | -- | -39.31 | -- | -20.31 | -- |
| Monte Rosa Therapeutics Inc | 0.00 | -135.35m | 273.34m | 133.00 | -- | 1.52 | -- | -- | -2.64 | -2.64 | 0.00 | 3.57 | 0.00 | -- | -- | 0.00 | -41.90 | -- | -47.16 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.75 | -- | -- | -- |
| Sanara Medtech Inc | 64.99m | -4.30m | 277.74m | 107.00 | -- | 6.13 | -- | 4.27 | -0.5219 | -0.5219 | 7.85 | 5.25 | 0.9635 | 1.90 | 8.37 | 607,381.70 | -6.58 | -17.73 | -8.17 | -22.07 | 87.92 | 88.08 | -6.83 | -17.13 | 1.04 | -18.75 | 0.1786 | -- | 41.77 | 61.93 | 45.79 | -- | 99.09 | -- |
| Anavex Life Sciences Corp | 0.00 | -43.16m | 278.36m | 40.00 | -- | 2.05 | -- | -- | -0.5357 | -0.5357 | 0.00 | 1.65 | 0.00 | -- | -- | 0.00 | -29.12 | -40.04 | -31.88 | -43.97 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 0.9857 | -- | -- | -- |
Data as of Apr 26 2024. Currency figures normalised to Inozyme Pharma Inc's reporting currency: US Dollar USD
44.81%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Adage Capital Management LPas of 31 Dec 2023 | 5.54m | 8.96% |
| Rock Springs Capital Management LPas of 31 Dec 2023 | 3.68m | 5.96% |
| Samlyn Capital LLCas of 31 Dec 2023 | 3.37m | 5.46% |
| Eventide Asset Management LLCas of 31 Dec 2023 | 3.18m | 5.15% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 2.82m | 4.56% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 2.33m | 3.78% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 2.27m | 3.68% |
| Affinity Asset Advisors LLCas of 31 Dec 2023 | 1.89m | 3.05% |
| Sphera Funds Management Ltd.as of 31 Dec 2023 | 1.56m | 2.53% |
| Geode Capital Management LLCas of 31 Dec 2023 | 1.03m | 1.67% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
